Physician profile
Matthew John Fordham
NPI 1659909349
$3,091.58
in general payments reported to CMS, 2019-2025
22 companies · $1,791 in 2025
The $1,791 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,301 · 2025: $1,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,958 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,958.14 |
| Education | $133.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,039.29 | 2024-2025 | Impella |
| Boston Scientific Corporation | $593.20 | 2024-2025 | General - Therapies, Avvigo Guidance System, Bodyguardian |
| Abbott Laboratories | $247.76 | 2024-2025 | Ensite, Navitor, Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $214.10 | 2024-2025 | Wainua, Lokelma |
| Edwards Lifesciences Corporation | $210.36 | 2024-2025 | |
| Cvrx, INC. | $134.85 | 2025 | Barostim Neo System |
| Shockwave Medical, INC | $113.40 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $110.47 | 2024-2025 | Lifevest |
| Scpharmaceuticals INC. | $91.55 | 2025 | |
| Bridgebio Pharma, INC. | $53.77 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $42.79 | 2025 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $37.88 | 2025 | |
| Novo Nordisk INC | $35.10 | 2025 | Wegovy |
| Baxter Healthcare | $26.00 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Esperion Therapeutics, INC. | $21.69 | 2025 | Nexletol |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $20.08 | 2024 | Onpattro |
| Novartis Pharmaceuticals Corporation | $19.99 | 2025 | |
| Chiesi USA, INC. | $17.95 | 2025 | Juxtapid |
| Regeneron Healthcare Solutions, INC. | $16.28 | 2025 | Evkeeza |
| Janssen Pharmaceuticals, INC | $15.98 | 2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $15.31 | 2025 | Eliquis |
| Actelion Pharmaceuticals US, INC. | $13.78 | 2025 | Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Fordham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.